Work

Supplementary Tables 1,2,3,4 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1: Inclusion and exclusion criteria. Supplementary Table 2: Lenalidomide dose reduction steps. Supplementary Table 3: Overall and complete response rates according to pre-treatment characteristics. Supplementary Table 4: Causes of death.

DOI: 10.1158/1078-0432.22459155

Authors: Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362432683

Cites:

Cited by:

Related to: 10